ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy

Core Insights - March Biosciences has been awarded a $200,000 G-Rex® Grant to advance the manufacturing of its lead asset, MB-105, a novel CAR-T cell therapy targeting CD5 for T-cell lymphomas [1][5]. Company Developments - The grant will support the development of a scalable cGMP process using the G-Rex bioreactor, aimed at reducing complexity, time, and costs in manufacturing autologous CAR-T products [2][4]. - March Biosciences is focused on overcoming scalability and efficiency barriers in the manufacturing of MB-105, with the support of Wilson Wolf Manufacturing [3][5]. - The G-Rex Grant will facilitate the establishment of a fully integrated CAR-T cell manufacturing process, enhancing the production capabilities for MB-105 and other CAR-T products in development [4][6]. Industry Context - The G-Rex Grant Program, which has awarded nearly 200 grants, aims to advance cell and gene-modified cell therapy (CGT) development and manufacturing, with individual grants worth up to $300,000 [6][8]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, indicating its significant role in the industry [8]. - March Biosciences' MB-105 has received U.S. FDA orphan drug designation for treating relapsed/refractory CD5-positive T-cell lymphoma, highlighting its potential in addressing unmet medical needs [5][14].